Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.38+0.10 (+1.37%)
Close on Nov 18, 2026Market cap $1.92BP/E –Yield –
Maravai LifeSciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Maravai LifeSciences's revenue for the twelve months ending Jun 30, 2026 was $208.78M, down 5.0% year over year. For fiscal 2025 it was $185.74M, down 28.3% from the year before. The highest annual figure on record is $883.00M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.74M | -28.3% |
| FY2024 | Dec 31, 2024 | $259.19M | -10.3% |
| FY2023 | Dec 31, 2023 | $288.95M | -67.3% |
| FY2022 | Dec 31, 2022 | $883.00M | +10.5% |
| FY2021 | Dec 31, 2021 | $799.24M | +181.3% |
| FY2020 | Dec 31, 2020 | $284.10M | +98.5% |
| FY2019 | Dec 31, 2019 | $143.14M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $51.44M | +8.5% |
| Q1 FY2026 | Mar 31, 2026 | $65.84M | +40.5% |
| Q4 FY2025 | Dec 31, 2025 | $49.87M | -11.8% |
| Q3 FY2025 | Sep 30, 2025 | $41.63M | -39.7% |
| Q2 FY2025 | Jun 30, 2025 | $47.40M | -31.7% |
| Q1 FY2025 | Mar 31, 2025 | $46.85M | -27.0% |
| Q4 FY2024 | Dec 31, 2024 | $56.56M | -23.7% |
| Q3 FY2024 | Sep 30, 2024 | $69.03M | +3.2% |
| Q2 FY2024 | Jun 30, 2024 | $69.42M | +0.7% |
| Q1 FY2024 | Mar 31, 2024 | $64.18M | -18.8% |
| Q4 FY2023 | Dec 31, 2023 | $74.14M | -63.8% |
| Q3 FY2023 | Sep 30, 2023 | $66.87M | -65.0% |
| Q2 FY2023 | Jun 30, 2023 | $68.91M | -71.6% |
| Q1 FY2023 | Mar 31, 2023 | $79.03M | -67.7% |
| Q4 FY2022 | Dec 31, 2022 | $204.71M | -10.4% |
| Q3 FY2022 | Sep 30, 2022 | $191.26M | -6.6% |
| Q2 FY2022 | Jun 30, 2022 | $242.73M | +11.5% |
| Q1 FY2022 | Mar 31, 2022 | $244.29M | +64.8% |
| Q4 FY2021 | Dec 31, 2021 | $228.44M | +132.3% |
| Q3 FY2021 | Sep 30, 2021 | $204.81M | +133.1% |
| Q2 FY2021 | Jun 30, 2021 | $217.78M | +364.3% |
| Q1 FY2021 | Mar 31, 2021 | $148.21M | +190.7% |
| Q4 FY2020 | Dec 31, 2020 | $98.35M | – |
| Q3 FY2020 | Sep 30, 2020 | $87.86M | – |
| Q2 FY2020 | Jun 30, 2020 | $46.91M | – |
| Q1 FY2020 | Mar 31, 2020 | $50.98M | – |
See a number that looks wrong?